What is liquid biopsy and how is it used for Lymphoma

Liquid Biopsy for Lymphoma: What You Need to Know

What Is a Liquid Biopsy?

A liquid biopsy is a blood test that detects cancer cells or cancer-related DNA fragments circulating in your bloodstream. Instead of removing tissue through a needle or surgical procedure, doctors analyze a small blood sample to look for signs of lymphoma and monitor how your body is responding to treatment.

Think of it this way: as cancer cells die or break apart—especially during treatment—they release fragments of their DNA into the blood. A liquid biopsy can detect these fragments, called circulating tumor DNA (ctDNA), which act like a "fingerprint" of your specific cancer.

How Liquid Biopsy Works for Lymphoma

The Testing Process

For lymphoma patients, liquid biopsy typically works in two stages:

1. Initial tumor analysis: Your doctors first examine your lymphoma tissue (from a biopsy) to identify the unique genetic "signature" of YOUR specific cancer cells
2. Blood monitoring: Blood samples are then tested to detect if those same cancer cell fragments are present

This is called a tumor-informed approach—the test is customized to look for YOUR cancer's specific DNA patterns.

Key Technology: Molecular Residual Disease (MRD) Testing

One important application is Molecular Residual Disease (MRD) testing, which detects remaining cancer cells after treatment. According to recent advances included in the NCCN Guidelines for B-Cell Lymphomas (December 2024), MRD testing using ctDNA can identify disease recurrence much earlier than traditional imaging.

For example, the Foresight CLARITY Lymphoma test—a ctDNA-based MRD assay—can detect relapse approximately 200 days (about 6-7 months) earlier than PET/CT imaging in patients with diffuse large B-cell lymphoma (DLBCL). In validation studies, this test correctly identified 90% of patients who later relapsed, compared to 45% detected by standard imaging.

Why This Matters for Your Lymphoma Care

Early Detection of Recurrence

Liquid biopsy can identify if lymphoma is returning before you develop symptoms or before it shows up on imaging scans. This "lead time" advantage gives your care team the opportunity to intervene earlier.

Treatment Monitoring

Your doctors can use liquid biopsy results to:

• Confirm whether treatment is working effectively
• Detect if new drug-resistant mutations are developing (as noted in the NCCN Guidelines for Marginal Zone Lymphomas, mutations can change during treatment)
• Guide decisions about continuing, changing, or stopping treatment

Personalized Surveillance

Rather than following a standard schedule of imaging scans, MRD results can help tailor your follow-up plan to YOUR specific situation.

Current Status and Availability

Important context: While liquid biopsy technology is advancing rapidly, availability varies:

• Research and clinical trials: Many lymphoma centers are actively studying MRD testing
• Limited clinical ordering: Some tests are available through specialized laboratories, though reimbursement and insurance coverage are still being established
• Emerging standard of care: The NCCN Guidelines now recognize ctDNA-MRD testing as an important tool for B-cell lymphomas, signaling growing clinical acceptance

Questions to Ask Your Lymphoma Care Team

Since liquid biopsy technology is evolving, here are important questions to discuss with your oncologist:

1. "Is liquid biopsy or MRD testing appropriate for my specific type of lymphoma?" (Different lymphoma subtypes may have different applications)
2. "Would MRD testing help guide my treatment decisions or surveillance plan?"
3. "Is this test available through your center, or would I need to go elsewhere?"
4. "How would the results affect my follow-up care or treatment decisions?"
5. "What is the cost, and will my insurance cover it?"

The Bottom Line

Liquid biopsy represents an exciting advancement in lymphoma monitoring that can detect cancer recurrence earlier and more sensitively than traditional methods. However, it's still a relatively new tool in clinical practice. Your oncologist can best determine whether it's appropriate for your specific situation and how it fits into your overall treatment and surveillance plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.